Resveratrol Trial for Relief of Pain in Pseudoachondroplasia

Inclusion Criteria: * The diagnosis of pseudoachondroplasia is based on clinical assessment either in person or by photographic review by skeletal dysplasia specialist (JTH), * Healthy beyond pseudoachondroplasia associated complications, Exclusion Criteria: * Current use of resveratrol * Current use of blood thinners, lovastatin, ketoconazole, itraconazole, fexofenadine and triazolam. * Other non-pseudoachondroplasia related health conditions, e.g. cancers. * Pregnancy or breastfeeding. Women must use adequate contraception during the study. * Participation in another clinical study and/or using investigational agents. * Use of Non-steroid anti-inflammatory (NSAIDs) or aspirin. * Current use of Alfentanil, Cyclosporine, Dihydroergotamine, Dofetilide, Ergotamine, Fentanyl, Flibanserin, Oxycodone, Pimavanserin, Pimozide, Quinidine, Saquinavir, Sirolimus, Tacrolimus, Temsirolimus, Theophylline, Tizanidine, Thioridazine, Fosphenytoin, Phenytoin or Warfarin. * Baseline level of pain of 2 or higher on 10 point scale. * Platelet count below 50,000 per ul on baseline complete blood count (CBC).